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Abstract
In this work we characterize an alcohol dehydrogenase (ADH) from the hyperthermophilic archaeon Pyrobaculum
aerophilum (PyAeADHII). We have previously found that PyAeADHII has no activity when standard ADH substrates are used
but is active when a-tetralone is used as substrate. Here, to gain insights into enzyme function, we screened several
chemical libraries for enzymatic modulators using an assay employing a-tetralone. The results indicate that PyAeADHII
activity in the presence of a-tetralone was inhibited by compounds such as flunarizine. We also examined metal
coordination of the enzyme in solution by performing metal substitution of the enzyme-bound zinc (Zn2+) with cobalt. The
solution-based absorption spectra for cobalt substituted PyAeADHII supports substitution at the structural Zn2+ site. To gain
structural insight, we obtained the crystal structure of both wild-type and cobalt-substituted PyAeADHII at 1.75 Å and 2.20 Å
resolution, respectively. The X-ray data confirmed one metal ion per monomer present only at the structural site with
otherwise close conservation to other ADH enzymes. We next determined the co-crystal structure of the NADPH-bound
form of the enzyme at 2.35 Å resolution to help define the active site region of the enzyme and this data shows close
structural conservation with horse ADH, despite the lack of a catalytic Zn2+ ion in PyAeADHII. Modeling of a-tetralone into
the NADPH bound structure suggests an arginine as a possible catalytic residue. The data presented here can yield a better
understanding of alcohol dehydrogenases lacking the catalytic zinc as well as the structural features inherent to
thermostable enzymes.
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Introduction
Alcohol dehydrogenases (ADHs; EC 1.1.1.1) are enzymes
widely distributed in all living organisms (archaea, bacteria, fungi,
plants and animals) [1] and play an important role in a broad
range of physiological processes (e.g. alcohol and alkane metab-
olism, cell defense towards exogenous alcohols and aldehydes) [2].
There are on-going efforts to structurally and functionally
characterize ADHs from hyperthermophilic bacteria (optimal
growth above 100uC). These ADHs are found to display extreme
stability at high temperature, high pressure, and high concentra-
tions of chemical denaturants, while also demonstrating broad
substrate specificity [3]. The ADH enzyme family can catalyze the
inter-conversion of a large number of compounds including
branched and cyclic alcohols, aliphatic and aryl aldehydes, linear,
branched and cyclic ketones and aliphatic and aryl-keto esters.
Many of the functional groups within these structures are also
found in chemical libraries employed in high-throughput screen-
ing (HTS) – large chemical libraries used to identify leads for drug
discovery and for studying chemical biology. This suggests that
screening ADH enzymes against HTS chemical libraries could
yield both inhibitors and substrates of the enzyme.
Enzymes such as ADH have the capability of catalyzing chemo-,
stereo- and regio-selective reactions to produce enantiomerically
pure products [4]. The thermostable feature of some of these
enzymes makes them commercially more attractive than their
mesophilic counterparts because the improved enzyme stability
offers considerably more potential for a range of biotechnological
applications in food, pharmaceutical and fine chemical industries
[5,6]. Thermostable structures can also make enzymes more
amenable to specific mutations aimed at designing enzymes that
catalyze unique chemical reactions.
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In the present work, our attention was focused on a
thermostable ADH from the hyperthermophilic archaeon Pyroba-
culum aerophilum (PyAeADHII) [7]. This ADH is characterized as
belonging to the medium-chain dehydrogenase/reductase (MDR)
superfamily, with a size of 330 residues and a structural Zn2+
binding site made up of four closely spaced cysteine residues
localized in a lobe at the periphery of the catalytic domain [8].
However, previous studies have revealed that PyAeADHII has
peculiar characteristics because the enzyme lacked activity on most
standard compounds used to test the activity of ADHs, and was
active only when a-tetralone was used as a substrate [9].
Moreover, sequence alignment of PyAeADHII with sequences of
well characterized ADHs, such as horse liver ADH (HLADH
6ADH_B) [10], Saccharomyces cerevisiae ADH (YADH CAA91579)
[11,12] and Sulfolobus solfataricus ADH (SsADH CAA87591) [13]
showed that the PyAeADHII lacks key residues involved in the
catalytic Zn2+binding (e.g. Cys-46, His-67 and Cys-174 in
HLADH; these are found as Asn-39, Ser-61, and Ile-147 in
PyAeADHII) and the key residue involved in the catalytic event,
corresponding to Ser-48 in YADH, Ser-40 in SsADH and Thr-45
in HLADH.
To identify potential probes acting as either substrates,
inhibitors, or activators of PyAeADHII, we screened libraries of
annotated low-molecular weight compounds (drugs or drug-like
compounds) using quantitative HTS (qHTS) – a paradigm in
which compounds in large chemical libraries are rapidly tested for
activity in an assay at multiple concentrations, thereby yielding
concentration-response curves (CRCs) for every compound, and
greatly reducing the frequency of false positives and false negatives
[14]. While we were unable to confirm substrates or activators of
the enzyme, the screen did identify a series of chemically-related
inhibitors with weak potency against the enzyme. Inhibition of the
enzyme by the compounds identified in the HTS was confirmed
using spectrophotometric assays, validating that these inhibitory
compounds are the first compounds known to inhibit PyAeADHII.
Additionally, we decided to undertake biophysical studies to
further characterize the thermostablity, metal coordination, and
NADPH binding of this MDR ADH. For these studies, we
substituted the PyAeADHII enzyme-bound Zn2+ with cobalt and
measured the spectral properties of the enzyme in solution, we
obtained the crystal structure of both wild-type (PyAeADHII-WT)
and cobalt-bound (PyAeADHII-Co) at 1.75 Å and 2.2 Å
resolution, respectively, and determined the co-crystal structure
of the NADPH-bound form (PyAeADHII-NADPH) of the enzyme
at 2.35Å resolution. The structural studies show strict homology to
other mesophilic ADHs despite the high thermostability and the
lack of a catalytic Zn2+ ion. Examination of the NADPH-bound
structures points to the catalytic region in PyAeADHII and an
arginine as a possible residue involved with catalysis.
Figure 1. PyeADHII inhibitors identified in the HTS. Top, structure of inhibitors, bottom table shows the potency data. CC = qHTS curve class.
None of the compounds showed autofluorescence.
doi:10.1371/journal.pone.0063828.g001
Figure 2. Inhibition of PyAeADHII at 706C by flunarizine
dihydrochloride. The assay was performed with 260 nM PyAeADHII
in 50 mM NaPO4 pH 7.5, 3 mM a-tetralone, 0.3 mM NADPH in the
presence of 80–1200 mM flunarizine dihydrochloride in DMSO/isopro-
panol. a) Absorbance of NADPH (340 nm) was measured over time at
different flunarizine concentrations. b) The rate of NADPH conversion
(Da.u. = absorbance unit change/minute) versus flunarizine concen-
tration.
doi:10.1371/journal.pone.0063828.g002
Figure 3. Absorption spectra of PyAeADHII Co-complex. The
lack of a weak band at 520 nm and the presence of the 740 nm band
indicates that cobalt was substituted at the structural site.
doi:10.1371/journal.pone.0063828.g003
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Materials and Methods
Spectrophotometric assay in standard conditions
The wild-type PyAeADHII was cloned and purified as
described elsewhere [9]. PyAeADHII activity was assayed at
37uC by measuring the change in absorbance of NADPH at
340 nm, using a Cary 1E spectrophotometer equipped with a
Peltier effect-controlled temperature cuvette holder. The standard
assay for the reduction reaction of a-tetralone was performed by
adding 2.6 mM final concentration of the enzyme to a preheated
assay mixture containing 3 mM substrate (a-tetralone; Sigma-
Aldrich #T19003, Lot S28914 or from Tokyo Chemical Industry
#T0134), 0.3 mM NADPH (Sigma-Aldrich #N5130) in 50 mM
sodium phosphate (pH 7.5) [15]. The protein concentration was
determined by spectrophotometry (Cary 1E, Varian). The molar
extinction constant for PyAeADHII was taken as E280
= 34,630 M21 cm21 and molecular weight of PyAeADHII is
approximately 38.5 kDa. This value is calculated based on fact
that the recombinant PyAeADHII contains an extraneous N-
terminus that is approximately 30 residues in length (containing a
His-tag) and the full-length PyAeADHII contains 360 residues, 12
of which are tyrosines and three are tryptophans. Under the
conditions described above the enzyme showed a Specific Activity
value of 0.08 U/mg. One unit of PyAeADHII is defined as the
enzyme amount required to oxidize 1 mmole of NADPH per min
at 37uC, on the basis of an absorption coefficient at 340 nm for
NADH of 6.22 mM21cm21.
Interestingly, we found that some samples of a-tetralone
purchased from Sigma-Aldrich and Tokyo Chemical Industry
appeared to contain small amounts of contaminating compounds
(as determined by mass spectrometry) that effectively inhibited
PyAeADHII activity. These contaminants needed to be removed
by HPLC in order to isolate pure a-tetralone.
Development of a PyAeADHII assay for HTS
An HTS assay was developed that utilized the fluorescence of
NADPH (lEx 340 nm/lEm 450 nm), a cofactor consumed in the
reduction of a-tetralone by PyAeADHII [9], as a read-out of
enzyme activity. Compounds that inhibit PyAeADHII would be
expected to decrease NADPH consumption by the enzyme, and
thus the fluorescence at 450 nm would be greater than uninhibited
enzyme. Conversely, activators of PyAeADHII would increase
consumption of NADPH, leading to decreased fluorescence at
450 nm relative to the control reaction (enzyme, NADPH, a-
tetralone, and DMSO).
Previous experiments identified a-tetralone as a substrate of
PyAeADHII [9]. These experiments were conducted at 70uC
using a spectrophotometer. Since the detector used to measure
NADPH fluorescence in high-throughput format (ViewLux plate
reader, PerkinElmer, Waltham, MA) did not have the capacity to
maintain this temperature, and because the detector did not have
the capacity to add reagent (thus requiring time for manual
loading of the assay plate after reagent addition and reaction
initiation), it was necessary to optimize the temperature that could
be used to initiate the reaction in parallel to optimizing the amount
of enzyme that would give sufficient activity at this temperature. In
addition, as the temperature of the assay plate would decrease to
room temperature over time in the detector, it was not possible to
perform a kinetic read for the HTS assay, and thus it was
necessary to determine a single time point at which to immediately
read the plate – a time point in which there was ,50% NADPH
consumption. Thus, prior to the HTS, optimization assays were
performed in which multiple concentrations of PyAeADHII were
tested, at different incubation temperatures, for different incuba-
tion times, with 3 mM a-tetralone and 0.3 mM NADPH, to
determine assay conditions amendable to a HTS.
Initially, different concentrations of PyAeADHII were tested for
activity at 25uC, 37uC, and 45uC using a spectrophotometer to
measure NADPH depletion (A340) over time, and then confirmed
using the fluorescence-based assay (all assays: 3 mM a-tetralone
and 0.3 mM NADPH). The temperature chosen to run the
fluorescence-based assay was 37uC, as the reaction rate proceeded
slow enough to allow time for the assay plate to be manually
loaded into the detector, but there was still enough activity to
reliably measure NADPH consumption after a 20 minute
incubation with substrate. Although the specific activity of the
Figure 4. The Zn2+ binding site of PyAeADHII. a) Zn2+ binding
in the active site of ADH-WT subunit A. The phased anomalous
map contoured at 5s calculated using the Zn-peak data, is shown as
blue mesh. b) Metal binding site for Co-substituted PyAeADHII with the
cobalt ion drawn as a red sphere. Phased anomalous difference maps
contoured at 5s were calculated using Co-peak data (orange) and Zn2+-
peak data (blue) and revealed that both ions were present.
doi:10.1371/journal.pone.0063828.g004
Figure 5. Superposition of ADH-NADPH (green) with YADH
(coral, PDB 2HCY) and HADH (blue, PDB 5ADH). Active site
ligands are drawn as cylinders and Zn2+ ions are represented as spheres.
doi:10.1371/journal.pone.0063828.g005
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enzyme is very low at this temperature (0.08 U/mg; [9], relatively
low concentrations (mM) of enzyme (e.g. low compared to the mM
substrate concentrations used) could be used to further optimize
the assay in 1536-well plates. Based on the results from these assays
(data not shown), a final concentration of enzyme at 2.6 mM was
chosen for subsequent assays at 37uC.
The PyAeADHII assay for qHTS
Kalypsys (San Diego, Ca) black polystyrene solid bottom 1,536-
well plates were used as assay plates. Polypropylene plates were
used as 1,536- well compound plates. Compounds from two
different chemical libraries were screened (compound number in
each collection is indicated in parentheses): the Sigma- Aldrich
LOPAC collection (1,280) and Tocris/TimTec (1,395; Bristol,
UK). These libraries were prepared as 7-point titrations that were
serially diluted 1:5 in dimethyl sulfoxide (DMSO) to establish a
concentration-response series starting from 10 mM stock concen-
tration to 0.64 mM. Each compound plate could contain up to
1,408 compound samples located in columns 5–48 with the first
four columns of each 1,536- well plate reserved for control
compounds. The wild-type PyAeADHII was cloned and purified
as described elsewhere [9]. In the assay, the control in the first
column was 6 mL of 0.3 mM NADPH (final concentration in the
assay; no enzyme control), in the second column, 6 mL of the
reaction mix with substrate (0.3 mM NADPH and 3 mM a-
tetralone, to test for fluorescent interference of a-tetralone, and
serving as a control for the maximal fluorescent signal possible
from experimental wells), in the third column 23 nL of DMSO,
0.3 mM NADPH, 3 mM a-tetralone, and 2.6 mM ADH was used
Figure 6. Active site view of ADH-NADPH (green) with YADH
(coral, PDB 2HCY) and HADH (blue, PDB 5ADH) (a). YADH and
HADH have adenosine-5-diphosphoribose and nicotinamide-8-iodo-
adenine-dinucleotide bound in the active site respectively. Active site
ligands are drawn as cylinders and active site Zn2+ ions for YADH and
HADH are represented as spheres. b) Superposition of ADH-WT
(magenta) and ADH-NADPH (green). The NADPH molecule and Cys
residues in the metal binding site are drawn as cylinders. The Zn2+ ions
associated with ADH-WT and ADH-NADPH are drawn as grey and blue
spheres respectively. Regions with the largest conformational differ-
ences are highlighted.
doi:10.1371/journal.pone.0063828.g006
Figure 7. Residues of PyAeADHII that form hydrogen bonds
with NADPH. Hydrogen bond interactions are shown as dashed lines
between NADPH and active site residues (green) for the ADH-NADPH
structure.
doi:10.1371/journal.pone.0063828.g007
Figure 8. Binding interaction of a-tetralone in the substrate
binding site of PyAeADHII/NADPH predicted by AutoDock. a)
Binding mode 1, a-tetralone was positioned on top of the nicotinamide
ring as a stacking interaction, and the oxygen atom formed a H-
bonding interaction with the side chain of residue Asn-39 (3.5 Å). b) a-
tetralone again forms stacking interaction with nicotinamide ring, but
the oxygen atom was orientated towards residue Arg-88 forming a H-
bonding interaction (3.0 Å). PyAeADHII is shown as a cartoon (green)
and residues in the substrate binding site are shown as sticks (carbon
colored in yellow, nitrogen in blue, oxygen in red). NADPH (carbons are
in grey) and the substrate a-tetralone (carbon are in orange) are shown
as sticks.
doi:10.1371/journal.pone.0063828.g008
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to determine basal activity of the enzyme in the presence of the
DMSO vehicle. For columns 5–48, which would be treated with
experimental compounds, three microliters/well of 26 PyAeAD-
HII- buffer solution (5.2 mM ADH, 50 mM Sodium phosphate
pH 7.5) was dispensed into 1,536-well assay plates with an Aurora
discovery BioRAPTR Flying Reagent Dispenser (FRD; Beckton-
Dickenson, Franklin Lakes, NJ). Using a Kalypsys pin tool
equipped with 1,536-pins, 23 nL of compound solution was
transferred to the assay plate, resulting in a final DMSO
concentration ,0.5%. The final compound concentrations in
the final assay volume thus ranged from 2.4 nM to 38 mM. After
adding compounds with the pin tool, the plates were initially read
with the ViewLux plate reader (Perkin Elmer, Waltham, MA),
using excitation wavelength of 340 nm and emission of 450 nm
(15,000 excitation energy, 5 s exposure time, 1x binning) to
identify any compounds that were fluorescent at these wave-
lengths. Following the pre-read of the plates, the reaction was
initiated upon addition of three microliters/well of substrate
buffer-solution (0.3 mM NADPH, 3 mM a-tetralone, 50 mM
Sodium phosphate pH 7.5) which was added using the FRD, to
yield a final reaction volume of 6 mL/well. After 20 mins of 37uC
incubation, fluorescence was detected with the ViewLux plate
reader (Perkin Elmer, Waltham, MA), using an excitation
wavelength of 340 nm and emission of 450 nm, 15,000 excitation
energy, 5 s exposure time, 16 binning.
Concentration-response curves (CRCs) were fitted to the data
allowing assignment of CRC classes that correspond to the efficacy
and potency of the compounds, the quality of the curve fits (r2)
derived from the Hill equation, and the number of asymptotes to
the calculated curve [16,17]. Based on this analysis, CRCs were
organized into four categories, defined as follows: Class 1a curves
were well fit (r2 $0.9), showed a full response (efficacy .80%), and
exhibited upper and lower asymptotes. Class 1b curves were the
same as Class 1a except the efficacy value (30–80%) indicated a
full but shallow curve. Class 2 curves were incomplete; they
contained only one asymptote and were divided into two
subclasses. Class 2a had a good fit (r2 $0.9) and a sufficient
response (efficacy .80%) to calculate an inflection point, whereas
Class 2b characterized a weaker response (efficacy ,80% and r2
,0.9). Class 3 curves displayed activity only at the highest tested
concentration with efficacy .30%. Class 4 assignments were
titrations with insufficient (efficacy ,30%) or no response and are
hereafter referred to as inactive. Hence, the library in its entirety
was defined as either active (Class 1–3) or inactive (Class 4) [16].
Spectrophotometric assays to confirm enzyme inhibition
Spectrophotometric assays were used as orthogonal assays to
confirm inhibition of PyAeADHII by flunarizine dihydrochloride
and other inhibitory compounds identified in the HTS assay.
These assays were performed as described above in the presence of
80 mM of inhibitor. The majority of compounds were assayed at
37uC with 2.6 mM PyAeADHII, however flunarizine dihydro-
chloride inhibition was also determined at 70uC (specific activity
4.75U/mg) with 260 nM PyAeADHII.
Bacterial growth in the presence of cobalt to produce
cobalt-bound PyAeADHII
To substitute the structural Zn2+ site with cobalt, the enzyme
was expressed in the presence of cobalt. Bacterial growth was
performed in minimal media M63 (100 mM potassium phosphate
pH 7.0, ammonium sulfate 15 mM, magnesium sulfate 1 mM,
0.4% glycerol and 1.8 nM iron sulfate heptahydrate). The starting
condition of bacterial growth to obtain the cobalt complex of
PyAeADHII was the same as that used to obtain the wild-type
PyAeADHII. However, at the time of induction, the bacterial
growth was centrifuged to eliminate the LB media and twice the
cellular pellet that was retained was re-suspended in 200 mL M63
media. After all components were mixed, approximately 50 g of
Chelex resin (BioRad #142–1253) was added to 1L of media to
remove Zn2+from the media. After one hour, the media was
filtered and sterilized using a Stericap Millipore 0.22 mm filter
(UFC5011008). The cells were then re-suspended in the Zn2+-free
M63 media and allowed to grow for about 20 minutes in the
shaker at 37uC. PyAeADHII expression was then induced with the
addition of IPTG (isopropylb-D-thio-galactopyranoside; Sigma-
Aldrich #I5502) and CoSO4 to a final concentration of 0.5 mM
and 10 mM, respectively. The growth of the bacterial culture
continued for 18 hours at 37uC to allow over-expression of the
putative Co-complex of PyAeADHII. The purification protocol
used was identical to that of wild-type PyAeADHII.
Crystallization, Data Collection and Structure Solution
Crystallization screening for all protein samples was conducted
using Compact Jr. (Emerald biosystems) sitting drop vapor
diffusion plates at 20uC. All X-ray diffraction data were at the
Advanced Photon Source IMCA-CAT beamline 17ID using a
Dectris Pilatus 6 M pixel array detector. Intensities were
integrated using XDS [18] and the Laue group determination
and data scaling were conducted with Aimless [19] which
indicated that P 2/m was the correct Laue class and the likely
space group was P21. All structure refinement and manual model
building with Phenix [20] and Coot [21] respectively. Structure
validation was carried out using Molprobity [22] and figures were
prepared using the CCP4 mg package [23].
Wild-type PyAeADHII (ADH-WT)
Wild–type recombinant PyAeADHII (described above and in
Vitale et al., [9]) was concentrated to 15.0 mg/mL in 250 mM
NaCl, 50 mM Na Phosphate pH 7.5, and 125 mM imidazole was
screened for crystallization. Plate shaped crystals were obtained in
1–2 days from the Wizard 2 screen condition #32 (Emerald
biosystems, 20% (w/v) PEG-1000, 100 mM Tris pH 8.5) using
0.5 mL of protein and 0.5 mL of crystallization solution equilibrat-
ed against 100 mL of the latter at 20o C. Single crystals were
transferred to a drop containing 80% crystallization solution and
20% PEG-400 before freezing in liquid nitrogen for data
collection. The Matthew’s coefficient (Vm = 2.43, 49.4% solvent)
suggested that there were 4 molecules in the asymmetric unit. An
X-ray fluorescence scan indicated that zinc was indeed present in
the crystals of the wild type PyAeADHII. Structure solution was
carried out by the SAD phasing method with Shelx C/D/E [24]
using zinc anomalous data to a resolution of 2.3 Å collected at a
wavelength of 1.28190 Å. Four zinc sites were located with ShelxD
and phasing with ShelxE yielded the following results: pseudo-free
CC = 50.79%/estimated mean FOM = 0.482 for the original and
pseudo-free CC = 72.80%/estimated mean FOM = 0.700 for the
inverted substructures respectively. Therefore, the inverted phases
were used from this point forward. A protein backbone model was
obtained using the auto-tracing routine in ShelxE which produced
a Ca model that was approximately 82% complete. The model
was improved further with ARP/wARP [25] followed by structure
refinement and manual model building. To confirm that the metal
sites were indeed Zn ions, a low energy remote data set was
collected using the same crystal at l= 1.2480 Å. No peaks were
observed in the anomalous difference map when using data
collected at this wavelength indicating that the metal assignment
was correct. A third data set was collected at l= 1.0000 Å which
was used for refinement of the final structure (PDB: 4JBG).
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Large difference density peaks (Fo-Fc) greater than 5s was
observed near Arg-323 of chains B, C and D which was originally
modeled as water molecules. However, following refinement this
site was covered with positive electron density (Fo-Fc) at a 5s
contour level indicating an underestimation of electrons. There-
fore, Cl- ions were modeled at these sites and no residual difference
density was observed following refinement. In addition, electron
density was observed at sites near Arg-197 on chains B and D that
was consistent with phosphate ions. Disordered side chains were
truncated to the point where difference electron density could be
observed.
Crystallization and Data Collection of Cobalt bound
PyAeADHII (ADH-Co)
A putative cobalt complex of PyAeADHII concentrated to
10.0 mg/mL in 500 mM NaCl, 50 mM NaPhosphate pH 7.5,
250 mM Imidazole was screened for crystallization. Plate shaped
crystals were obtained in 1–2 days from the Wizard 4 screen
condition #22 (Emerald biosystems, 25%(w/v) PEG 1500 PCB
Buffer 7.0) using 0.5 mL of protein and 0.5 mL of crystallization
solution equilibrated against 100 mL of the latter. Single crystals
were transferred to a drop containing 80% crystallization solution
and 20% 2-methyl-2,4-pentanediol (MPD) before freezing in
liquid nitrogen for data collection. This structure was isomorphous
to the previously determined wild-type ADH structure and
contained 4 molecules in the asymmetric unit. An X-ray
fluorescence scan indicated that cobalt was indeed present in the
crystals. However, since the cobalt-complex was prepared from
wild-type protein that contained Zn2+ ions, an X-ray fluorescence
scan for Zn2+ was conducted as well which indicated that Zn2+
ions were also present. Structure solution was carried out by
molecular replacement with Phase [26] via the Phenix [20]
interface using ADH-WT as the search model. X-ray diffraction
data for cobalt- bound PyAeADHII were collected at the following
wavelengths using the same crystal: 1.60497 Å (cobalt-peak),
1.61018 Å (cobalt-low energy remote) and 1.28255 Å (Zn2+-peak).
Phased anomalous difference maps were calculated using FFT
[27] though the CCP4 [28] interface. Anomalous difference peaks
were observed in the active sites using the cobalt-peak data.
However, no peaks were observed using the cobalt-low energy
remote data confirming that cobalt was present in the active sites.
Likewise, anomalous difference peaks were present in the metal
binding site using the Zn2+-peak data. Therefore, both Zn2+ and
cobalt ions were modeled at these sites with 0.5 occupancies in the
final structure (PDB: 4JBH).
Crystallization and Data Collection of PyAeADHII bound
to NADPH (ADH-NADPH)
The wild type ADH construct described above was incubated
with 5 mM NADPH for 30 minutes in ice prior to screening. Plate
shaped crystals were obtained in 1–2 days from the Wizard 3
screen condition #12 (Emerald biosystems, 10% (w/v) PEG 8000,
100 mM Hepes pH 7.5, 8%(v/v) ethylene glycol). Single crystals
were transferred to a drop containing 75% crystallization solution
and 25% ethylene glycol before freezing in liquid nitrogen for data
collection. The Matthew’s coefficient [29] was calculated based on
an estimated molecular weight of 35,481 Da and indicated that
there were most likely 16 molecules in the asymmetric unit
(Vm = 2.8, 55.4% solvent; Figure S1). An initial solution was
obtained by molecular replacement, using the coordinates from
ADH-WT structure as the search model, with Phaser [26] within
the Phenix [20] software package. Following refinement, the R-
factor converged at approximately 35%. Examination of the
resulting electron density maps revealed that certain residues near
the NADPH binding pocket were in an incorrect conformation
relative to the apo protein used for the search model. The model
was then improved using the autobuilding suite within Phenix and
a single subunit from the resulting model was used for subsequent
molecular replacement searches with Molrep [30] to position the
final four molecules. Following refinement of the 16 molecules,
positive difference electron density (Fo-Fc) greater than 3s was
observed in the active sites of each subunit and was consistent with
NADPH (Figure S2). However, it could not be determined if the
ligand existed in the NADP+ form and was therefore modeled as
NADPH. After fitting the NADPH molecules, the final structure
was improved with subsequent rounds of refinement and manual
model building (PDB: 4JBI).
Structure Comparison with apo ADH and modeling of a-
tetralone
For comparison, chain A of apo PyAeADHII was superimposed
onto chain A of the NADPH bound structure from residue Met 1
to Pro 331 (328 residues, chain A) using Superpose [31].
Modeling of a-tetralone in the active site of PyAEADHII
The binding model of substrate a-tetralone in the active site of
PyAEADHII was predicted using a protocol with molecule
docking and MD simulations, as reported previously [32]. Briefly,
a-tetralone was docked into the active site of PyAeADHII/
NADPH using AutoDock 4.2 [33]. The Lamarckian Genetic
Algorithm (LGA) was applied to search the entire binding site of
the protein which was defined by a grid of 70670670 points with
a grid spacing of 0.5 Å centered at the co-factor NADPH. A total
of 100 runs were generated and the maximum number of energy
evaluations was set to 26106. Clustering analysis of the docked
poses was performed using AutoDockTools [33] to identify the
major binding modes based on the root-mean standard deviations
(RMSD). To optimize the binding models, MD simulations were
conducted for the ADH/NADPH/a-tetralone binding complex in
explicit solvent using the AMBER 11 package with the ff99SB
force field [34]. The solvated protein systems were first subjected
to a gradual temperature increase from 0 K to 300 K over 100 ps,
and then equilibrated for 500 ps at 300 K, followed by production
runs of 2 ns length in total. Constant temperature and pressure
(300 K/1 atm) were maintained during the time course of
simulations with a time constant for heat-bath coupling of 0.2
ps. Trajectory analysis and the binding free energy calculations
were performed using the PTRAJ and MMPBSA modules in the
AMBER 11 package.
Results and Discussion
Miniaturized PyAEADHII assay for quantitative high-
throughput screening (qHTS)
Working with hyperthermophilic enzymes is technically chal-
lenging in a typical laboratory environment due to the high
temperatures required to yield the highest specific activity for these
enzymes. Our previous work identified a-tetralone as a potential
substrate for PyAeADHII, with a-tetralone converted to a-tetralol
and oxidation of the coenzyme NADPH to form NADP+. For low-
throughput experiments, we monitor NADPH oxidation as a
decrease in A340 using a spectrophotometer. However, to make the
assay more amenable to high-throughput formats, we measured
the fluorescence of NADPH (lex = 340 nm, lem = 450 nm) using
qHTS. In this mode the fluorescence signal in the assay decreases
as NADPH is converted to NADP+.
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Designing a high-throughput assay to screen for inhibitors of a
hyperthermophilic enzyme like PyAEADHII is additionally
challenging for a number of reasons. The first such challenge is
that PyAEADH11 is catalytically most active at temperatures
higher than 50uC [9] – temperatures that are difficult to maintain
during the course of the reaction using the equipment necessary
for HTS. For this reason, significant assay optimization was
required to determine the concentration of enzyme that could be
used in the assay at 25uC or 37uC –temperatures more amenable
for use with HTS – such that sufficient substrate/coenzyme
conversion took place within a certain time-course (see Materials
and Methods for more details). Another challenge specific to
working with this enzyme is that PyAeADHII shows very low
activity for a-tetralone, the only known substrate for PyAeADHII,
even at optimal temperatures [9], with mM levels of enzyme and
mM concentrations of substrate required to measure sufficient
activity. In spite of these significant challenges, however, we were
able to identify a number of compounds that inhibited
PyAeADHII using this high-throughput assay.
Another factor we considered when developing the assay was
the effect of compound fluorescence on the assay results. Small
molecule libraries, which contain a relatively high percentage of
heterocyclic compounds with low levels of conjugation, are known
to contain a significant fraction of compounds with blue
fluorescence (,5% of these libraries) which can interfere with
fluorescence-based assay results when shorter excitation and
emission wavelengths are used (lem ,350 nm; lex = 450–
490 nm) [35,36]. For this reason we incorporated a step in the
protocol in which the fluorescent signal from the plate was read
post-compound addition, but prior to initiation of the reaction.
The final 1,536-well protocol for library screening is described in
the Table S1.
We used this 1,536-well protocol to screen two libraries
containing a total of approximately 2,700 compounds at seven
concentration points. These libraries contained a variety of
scaffolds, some of which contained alcohol and ketone groups,
which could serve as more optimal ADH substrates, in addition to
possibly acting as inhibitors or activators of the enzyme. For each
assay plate we calculated the signal-to-background ratio (SB) and
the Z’ factor [37]. The screen performed well with minimal well-
to-well variation (5%), a SB of approximately 3-5-fold, and Z’
factors of between 0.5 and 0.9. From the screen, we were able
confirm six compounds of a similar chemotype that showed an
inhibitory effect on PyAeADHII, with IC50s ranging from 10 to
60 mM, and efficacies, for most, of approximately 30% (Figure 1).
One compound, flunarizine dihydrochloride, had an efficacy of
60%. The activity of these compounds was confirmed using the
spectrophotometry assay at 37uC. Inhibition of PyAeADHII by
flunarizine dihydrochloride was also demonstrated in a more
relevant assay conducted at 70uC (50–70% inhibition; Figure 2)
with a significantly lower concentration of enzyme (260 nM). Thus
the HTS assay developed was able to identify the first compounds
known to inhibit hyperthermophilic PyAeADHII.
Cobalt(II) substituted PyAeADHII
The sequence alignment obtained by comparing PyAeADHII,
Sulfolobus solfataricus ADH (SsADH), Saccharomyces cerevisiae ADH
(YADH) and horse liver ADH (HLADH) sequences [9], revealed
that the structural Zn2+-binding site was conserved in PyAeADHII
and that this enzyme lacked the key residues involved in
coordinating to the catalytic Zn2+. To obtain experimental
evidence for the coordination environment of the zinc sites in
PyAeADHII in solution, we replaced the spectroscopically silent
Zn2+ with cobalt [38]. Standard methods for cobalt substitution of
the catalytic Zn2+ site involve the removal and the replacement of
Zn2+from purified enzymes using chelating agents such as
dipicolinic acid followed by dialysis, addition of cobalt, and
dialysis again. In some cases, at the appropriate pH, direct metal
exchange of the catalytic Zn2+ site can also be achieved [39,40].
Metal substitution of the structural Zn2+ site is much more difficult
to achieve. To address this, a method for direct cobalt
incorporation in the Zn2+ binding sites of metal-enzymes by
bacterial growth in the presence of Zn2+-depleted and cobalt-
enriched media, was performed (see Materials and Methods).
The absorption spectrum of the putative ADH-cobalt complex
is shown in Figure 3. The spectrum shows the characteristic
ligand-metal charge transfer band at 340 nm in addition to
absorbance peaks in the visible region. In HLADH, the visible
electronic absorption spectrum of the cobalt-substituted enzyme
that contains cobalt only at the catalytic site, is characterized by a
major absorbance peak at 640 nm and two minor peaks at
530 nm and 550 nm [38]. However, when the Zn2+ ion is
replaced by cobalt at the structural site, the spectra shows a
characteristic absorption peak at 740 nm in addition to the
640 nm peak [38]. The spectra recorded by the cobalt-substituted
PyAeADHII gave broad peaks at 740–750 nm and 640 nm,
characteristic of cobalt insertion at the structural site, but not in
the 530–550 nm region (which is characteristic of the cobalt
substitution at the catalytic site). However, due to the fact that the
known absorbance peaks found for the catalytic site in HLADH
(530–550 nm region) are typically weak, it was difficult to
determine if cobalt was also substituted at a putative catalytic
site. Therefore, although this experiment was able to conclusively
demonstrate that cobalt was substituted at the structural Zn2+ site,
and confirm that wild-type PyAeADHII thus contains structural
Zn2+, it could not definitively conclude whether or not the enzyme
contained an additional Zn2+ site.
Crystal Structure and X-ray fluorescence of wild-type and
cobalt-substituted PyAeADHII
We determined the X-ray structure of wild-type PyAeADHII at
1.75 Å (crystallographic data summarized in Table S2). Four
molecules of ADH were found in the asymmetric unit with each
monomer containing its own structural Zn2+ (Figure S3). To
confirm that the metal-binding sites in the wild-type enzyme were
complexed to Zn2+, a low energy remote data set was collected
using the same crystal at l= 1.2480 Å. No peaks were observed in
the anomalous difference map when using data collected at this
wavelength, indicating that the metal assignment was correct
(Figure 4a). This result thus confirms the hypothesis (generated
from sequence alignment analysis and the absorption spectra of
the cobalt substituted enzyme) that only the structural Zn2+site is
present in PyAeADHII. The Cys-Zn2+ distances are: Cys-91
= 2.31Å, Cys-94 = 2.29Å, Cys-97 = 2.32Å and Cys-105 = 2.32Å
(Figure 4a). Therefore, this structural site shows Cys-Zn2+ ligand
distances which are akin to peptide-zinc model systems, as
opposed to what has been observed in some ADH enzymes where
longer Cys-Zn2 distances have been observed (2.69 Å) suggesting
an entatic state for this site in these enzymes [41].
We also determined the X-ray structure of the cobalt substituted
PyAeADHII at 2.20 Å (Table S2). Anomalous difference peaks
were observed in the active sites using the cobalt-peak data.
However, no peaks were observed using the cobalt-low energy
remote data, confirming that cobalt was present in the structural
metal binding site. Likewise, anomalous difference peaks were
present in the structural metal binding site using the Zn2+-peak
data. Therefore, both Zn2+ and cobalt ions were modeled at these
sites with 0.5 occupancies. Anomalous difference maps for the
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metal binding site in subunit A is shown in Figure 4b. These data
indicate that the incorporation of cobalt within the structural sites
was partial, and the presence of cobalt did not change the folding
of the enzyme.
Comparison of PyAeADHII structure to other ADH
enzymes
To examine the structural overlap with higher order organisms,
the three-dimensional structure of PyAEADHII was compared
with horse liver (HADH, PDB: 5ADH), and yeast (YADH, PDB:
2HCY) alcohol dehydrogenases which indicated that a similar fold
is adopted (Figure 5). The superposition of HADH and YADH
with ADH-NADPH was conducted using secondary structure
matching [31] at 1.73 Å (309 residues) and 1.92 Å (319 residues),
respectively. Consistent with other studies which have compared
mesophilic and thermophiliic homologues [9], the arrangement of
secondary and tertiary structures doesn’t explain the large
difference in stability.
It has been suggested that increased thermostability of certain
alcohol dehydrogenases may likely be attributed to the increased
number of proline residues located at specific sites such as coil/
loop regions which serve to stabilize the global structure [42]. It
was noted, for example, that ADH from the thermophilic bacteria
Thermoanaerobacter brockii (TBADH) and HADH contain a high
number of proline residues (21 and 19 respectively) relative to
YADH which contains 13 proline residues [43]. PyAeADHII
contains 19 proline residues of which 14 reside in coil/loop regions
of the protein. A comparison of the proline residue distribution for
PyAeADHII, TBADH (PDB: 1YKFl, [44]), HADH and YADH is
shown in Figure S4. Notably, the proline residues in PyAeAD-
HII, TBADH and HADH are distributed throughout the protein
whereas in YADH, the prolines are localized in the N-terminal
and central regions of the protein. This distribution of proline
residues in PyAeADHII may therefore contribute to its observed
thermostability.
Co-crystal structure of PyAeADHII with NADPH and
analysis of the putative active site
To better define the active site of PyAeADHII, we determined
the co-crystal structure of PyAeADHII monomer bound to
NADPH (Figure S1; PDB: 4JBI). This co-crystal structure
revealed a similar binding mode for NADPH in PyAeADHII as
is found for other ligands in the HADH and YADH enzymes
(Figure 6a). The NADPH bound structure is similar to apo
PyAeADHII with an overall RMSD of 1.02 Å between Ca atoms
(Figure 6b). However, certain regions near the NADPH binding
site undergo conformational changes to accommodate ligand
binding. Specifically, the residues between Asp-230 to Ser-240,
Ala-253 to Val-261 and Glu-316 to Val-324 are in different
conformation in the NADPH bound structure (Figure S5 and
S6). Both Arg-323 and 326 conform to bind to the phosphates of
NADPH and the main-chain NH of Ala-253 form H-bonds with
the nicotinamide carbonyl which involves movement of a loop
region (see Figure 7, Figure S6, and Movie S1). Similarly, the
active site ligands for HADH and YADH adopt various hydrogen
bonds to the protein residues (Figure S7a and b). The main
difference, apart from the distinct amino acid residues that interact
with the ligands for each structure, is the lack of a Zn2+ ion in the
active site for PyAeADHII – NADPH as is present for HADH and
YADH (Figure S7c). The active site Zn2+ is coordinated by two
Cys residues and a His residue for HADH and YADH. However,
ADH-NADPH does not contain the requisite amino acid residues
in this region for metal coordination but instead Asn-39, Ser-61
and Ile-147 occupy this region. The Cys ligands in the structural
Zn2+ site show little change between apo and NADPH bound
structures (Figure S8).
Modeling of a-tetralone into the NADPH-bound structure
To possibly identify residues in the active site of PyAeADHII we
modeled the substrate a-tetralone into the NADPH-bound
structure. Two plausible binding modes of the substrate in the
active site were predicted from docking analysis (Figure 8). In the
first binding mode, a-tetralone was positioned on top of the
nicotinamide of NADPH forming p-stacking interaction, while the
carbonyl oxygen atom pointed towards residues Asn39 in the deep
binding pocket and formed a hydrogen-bonding interaction
(Figure 8a). In the second binding model the substrate was
bound in the active site of PyAeADHII in a similar manner (being
situated on top of the nicotinamide of NADPH), but the oxygen
atom was orientated on the opposite side and formed hydrogen-
bonds with residue Arg-88 (Figure 8b). Further MD simulations
showed that a-tetralone in the two binding models remained stable
and the calculated binding free energies were comparable.
Without a catalytic zinc ion in the active site, a-tetralone is
accommodated well in the binding pocket of PyAeADHII. The
binding affinities for a-tetralone appear to be mainly due to an
aromatic stacking interaction with the nicotinamide ring of
NADPH and H-bonding with either residue Arg-88 or Asn-39
in the two binding models. Asn-39 is a cysteine involved with
Zn2+- coordination in other ADHs and is unique to PyAeADHII.
Arg-88 is unique to PyAeADH – in HADH, Thr-94 is involved
with this H-bonding, and in YADH, this residue is Leu-93. It is
possible that Arg-88 acts to stabilize the oxyanion in the active site
and upon hydride transfer this residue could donate a proton to
form the alcohol.
Conclusion
We studied both the functional and structural details of a
thermostable ADH from archaea P. aerophilum with a substrate
specificity and catalytic mechanism different than other well
characterized medium- chain Zn- dependent ADH enzymes
which contain both structural and catalytic Zn2+ ions. Short-
chain dehydrogenases/reductases (SDR) are a large family of
NADP(H)-dependent oxidoreductases that also contain the classic
Rossmann fold motif for nucleotide binding but do not contain
Zn2+ [45]. PyAeADHII, possessing only the structural Zn2+ site,
may be a hybrid between Zn2+-dependent medium-chain ADHs
and non- Zn2+ dependent SDRs. The characterization of this
unique ADH presented here expands our understanding of the
class of ADH enzymes and could help the design of thermostable
dehydrogenases/reductases with new catalytic mechanisms.
Supporting Information
Figure S1 Asymmetric unit of ADH-NADPH showing the
16 molecules colored by chain. The Zn2+ ions are drawn as
grey spheres and NADPH molecules are shown as cylinders.
(TIF)
Figure S2 Fo-Fc omit map contoured at 3 s for the
NADPH molecule associated with chain A in the ADH-
NADPH structure.
(TIF)
Figure S3 The four molecules of ADH in the asymmetric
unit colored by subunit. Zinc ions are represented at grey
spheres.
(TIF)
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Figure S4 Comparison of the distribution of proline
residues (red) in ADH-NADPH (green), HADH (blue,
PDB: 5ADH), TBADH (gold, PDB: 1YKF) and YADH
(coral, PDB: 2HCY). The structural Zn2+ ions are represented
as spheres except for TBADH which does not contain a Zn2+ ion
in this region.
(TIF)
Figure S5 Plot of RMSD deviations per residue between
Ca atoms of ADH-WT and ADH-NADPH.
(TIF)
Figure S6 Superposition of ADH-NADPH (green) and
ADH-WT (magenta) showing the conformational chang-
es observed in regions near the NADPH binding site. The
NADPH molecule is drawn as cylinders.
(TIF)
Figure S7 Hydrogen bond interactions between the
active site ligands and protein for a) HADH and b)
YADH. C) Active site metal binding region for HADH (blue),
YADH (coral) superimposed with ADH-NADPH (green). Zn2+
ions are drawn as spheres.
(TIF)
Figure S8 Comparison of the Zn2+ binding site for ADH-
WT (magenta) and ADH-NADPH (green). The Zn2+ ions
associated with ADH-WT and ADH-NADPH are drawn as grey




Table S1 1536 well protocol of PyAeADHII assay at
376C.
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Table          Crystallographic data for PyAeADHII.
(DOCX)
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